Kristen Ann Stout - Publications

Affiliations: 
Emory University, Atlanta, GA 
Area:
VMAT2, dopamine signaling

21 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Stout K, Dunn A, Hoffman C, Miller GW. The synaptic vesicle glycoprotein 2: structure, function, and disease relevance. Acs Chemical Neuroscience. PMID 31394034 DOI: 10.1021/acschemneuro.9b00351  0.96
2019 Manvich DF, Petko AK, Branco RC, Foster SL, Porter-Stransky KA, Stout KA, Newman AH, Miller GW, Paladini CA, Weinshenker D. Selective D and D receptor antagonists oppositely modulate cocaine responses in mice via distinct postsynaptic mechanisms in nucleus accumbens. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 30879021 DOI: 10.1038/s41386-019-0371-2  0.96
2017 Dunn AR, Hoffman CA, Stout KA, Ozawa M, Dhamsania RK, Miller GW. Immunochemical Analysis Of The Expression Of Sv2c In Mouse, Macaque And Human Brain. Brain Research. PMID 29274878 DOI: 10.1016/j.brainres.2017.12.029  0.96
2017 Dunn AR, Stout KA, Ozawa M, Lohr KM, Hoffman CA, Bernstein AI, Li Y, Wang M, Sgobio C, Sastry N, Cai H, Caudle WM, Miller GW. Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease. Proceedings of the National Academy of Sciences of the United States of America. PMID 28246328 DOI: 10.1073/pnas.1616892114  0.96
2016 Patel R, Bradner JM, Stout KA, Caudle WM. Alteration to Dopaminergic Synapses Following Exposure to Perfluorooctane Sulfonate (PFOS), in Vitro and in Vivo. Medical Sciences (Basel, Switzerland). 4. PMID 29083377 DOI: 10.3390/medsci4030013  0.68
2016 Cliburn RA, Dunn AR, Stout KA, Hoffman CA, Lohr KM, Bernstein AI, Winokur EJ, Burkett J, Shmitz Y, Caudle WM, Miller GW. Immunochemical localization of vesicular monoamine transporter 2 (VMAT2) in mouse brain. Journal of Chemical Neuroanatomy. PMID 27836486 DOI: 10.1016/j.jchemneu.2016.11.003  0.96
2016 Stout KA, Dunn AR, Lohr KM, Alter SP, Cliburn RA, Guillot TS, Miller GW. Selective enhancement of dopamine release in the ventral pallidum of methamphetamine-sensitized mice. Acs Chemical Neuroscience. PMID 27501345 DOI: 10.1021/acschemneuro.6b00131  0.96
2016 Lohr KM, Chen M, Hoffman CA, McDaniel MJ, Stout KA, Dunn AR, Wang M, Bernstein A, Miller GW. Vesicular monoamine transporter 2 (VMAT2) level regulates MPTP vulnerability and clearance of excess dopamine in mouse striatal terminals. Toxicological Sciences : An Official Journal of the Society of Toxicology. PMID 27287315 DOI: 10.1093/toxsci/kfw106  0.88
2016 Farrell MS, McCorvy JD, Huang XP, Urban DJ, White KL, Giguere PM, Doak AK, Bernstein AI, Stout KA, Park SM, Rodriguiz RM, Gray BW, Hyatt WS, Norwood AP, Webster KA, et al. In Vitro and In Vivo Characterization of the Alkaloid Nuciferine. Plos One. 11: e0150602. PMID 26963248 DOI: 10.1371/journal.pone.0150602  0.88
2016 Trossbach SV, Bader V, Hecher L, Pum ME, Masoud ST, Prikulis I, Schäble S, de Souza Silva MA, Su P, Boulat B, Chwiesko C, Poschmann G, Stühler K, Lohr KM, Stout KA, et al. Misassembly of full-length Disrupted-in-Schizophrenia 1 protein is linked to altered dopamine homeostasis and behavioral deficits. Molecular Psychiatry. PMID 26754951 DOI: 10.1038/mp.2015.194  0.96
2015 Alter SP, Stout KA, Lohr KM, Taylor TN, Shepherd KR, Wang M, Guillot TS, Miller GW. Reduced vesicular monoamine transport disrupts serotonin signaling but does not cause serotonergic degeneration. Experimental Neurology. PMID 26428905 DOI: 10.1016/j.expneurol.2015.09.016  0.88
2015 Vieira-Brock PL, McFadden LM, Nielsen SM, Ellis JD, Walters ET, Stout KA, McIntosh JM, Wilkins DG, Hanson GR, Fleckenstein AE. Chronic Nicotine Exposure Attenuates Methamphetamine-Induced Dopaminergic Deficits. The Journal of Pharmacology and Experimental Therapeutics. PMID 26391161 DOI: 10.1124/jpet.114.221945  0.88
2015 Lohr KM, Stout KA, Dunn AR, Wang M, Salahpour A, Guillot TS, Miller GW. Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity. Acs Chemical Neuroscience. 6: 790-9. PMID 25746685 DOI: 10.1021/acschemneuro.5b00010  0.88
2014 Lohr KM, Bernstein AI, Stout KA, Dunn AR, Lazo CR, Alter SP, Wang M, Li Y, Fan X, Hess EJ, Yi H, Vecchio LM, Goldstein DS, Guillot TS, Salahpour A, et al. Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo. Proceedings of the National Academy of Sciences of the United States of America. 111: 9977-82. PMID 24979780 DOI: 10.1073/pnas.1402134111  0.88
2014 Bernstein AI, Stout KA, Miller GW. The vesicular monoamine transporter 2: an underexplored pharmacological target. Neurochemistry International. 73: 89-97. PMID 24398404 DOI: 10.1016/j.neuint.2013.12.003  0.88
2013 Bradner JM, Suragh TA, Wilson WW, Lazo CR, Stout KA, Kim HM, Wang MZ, Walker DI, Pennell KD, Richardson JR, Miller GW, Caudle WM. Exposure to the polybrominated diphenyl ether mixture DE-71 damages the nigrostriatal dopamine system: role of dopamine handling in neurotoxicity. Experimental Neurology. 241: 138-47. PMID 23287494 DOI: 10.1016/j.expneurol.2012.12.013  0.88
2012 Bernstein AI, Stout KA, Miller GW. A fluorescent-based assay for live cell, spatially resolved assessment of vesicular monoamine transporter 2-mediated neurotransmitter transport. Journal of Neuroscience Methods. 209: 357-66. PMID 22698664 DOI: 10.1016/j.jneumeth.2012.06.002  0.88
2012 McFadden LM, Stout KA, Vieira-Brock PL, Allen SC, Nielsen SM, Wilkins DG, Hanson GR, Fleckenstein AE. Methamphetamine self-administration acutely decreases monoaminergic transporter function. Synapse (New York, N.Y.). 66: 240-5. PMID 22120988 DOI: 10.1002/syn.21506  0.88
2012 McFadden LM, Hadlock GC, Allen SC, Vieira-Brock PL, Stout KA, Ellis JD, Hoonakker AJ, Andrenyak DM, Nielsen SM, Wilkins DG, Hanson GR, Fleckenstein AE. Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure. The Journal of Pharmacology and Experimental Therapeutics. 340: 295-303. PMID 22034657 DOI: 10.1124/jpet.111.188433  0.88
2011 McFadden LM, Hoonakker AJ, Vieira-Brock PL, Stout KA, Sawada NM, Ellis JD, Allen SC, Walters ET, Nielsen SM, Gibb JW, Alburges ME, Wilkins DG, Hanson GR, Fleckenstein AE. Methamphetamine treatment during development attenuates the dopaminergic deficits caused by subsequent high-dose methamphetamine administration. Synapse (New York, N.Y.). 65: 771-7. PMID 21190217 DOI: 10.1002/syn.20902  0.88
2010 Chu PW, Hadlock GC, Vieira-Brock P, Stout K, Hanson GR, Fleckenstein AE. Methamphetamine alters vesicular monoamine transporter-2 function and potassium-stimulated dopamine release. Journal of Neurochemistry. 115: 325-32. PMID 20649837 DOI: 10.1111/j.1471-4159.2010.06922.x  0.88
Show low-probability matches.